NEXTECH INVEST LTD
Q1 2023 Form 13-F
ZURICH
CIK 0001911010
· CRD 322629
· Exempt reporting adviser
$239.6M Reported Value Total
Exempt Reporting Adviser
nextechinvest.com
Source: Form ADV filed 2026-03-27
Reported value
$239.6M
Quarter over quarter
-1.7%
Holdings
12
Top-10 concentration
98.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Marco Weibel
Chief Financial Officer
Filing Navigation
13F Metrics
Loading 13F Metrics
Q1 2023 13F record
Q1 2023 13F filing summary
| Period of report | March 31, 2023 |
|---|---|
| Filed | May 12, 2023 |
| Form | 13F-HR |
| Reported value | $239.6M |
| Positions | 12 |
| Change in reported value | -4.7% |
| New positions | 0 |
| Exited positions | 2 |
| Position turnover | 14.3% |
| Top-10 concentration | 98.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
15 | $616.4M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
15 | $712.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
13 | $594.5M |
|
Q1 2024 13F
Filed May 15, 2024
|
12 | $630.8M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
11 | $536.8M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
14 | $330.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
13 | $294.2M |
|
Q1 2023 13F
Filed May 12, 2023
|
12 | $239.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
14 | $251.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
14 | $309.6M |
|
Q2 2022 13F
Filed Aug 1, 2022
|
14 | $296.5M |
|
Q1 2022 13F
Filed May 16, 2022
|
14 | $350.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
11 | $379.6M |
Top 12 holdings · Q1 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | $104.8M | 43.76% |
| 2 | TYRA TYRA BIOSCIENCES INC | $40.5M | 16.89% |
| 3 | EQRX EQRX INC | $25.4M | 10.61% |
| 4 | KNTE KINNATE BIOPHARMA INC | $14.6M | 6.08% |
| 5 | CGEM CULLINAN ONCOLOGY INC | $12.5M | 5.21% |
| 6 | SPRY ARS PHARMACEUTICALS INC | $12.4M | 5.19% |
| 7 | RLAY RELAY THERAPEUTICS INC | $10.3M | 4.3% |
| 8 | ARVN ARVINAS INC | $7.8M | 3.28% |
| 9 | THRX THESEUS PHARMACEUTICALS INC | $5.4M | 2.27% |
| 10 | PMVP PMV PHARMACEUTICALS INC | $2.5M | 1.04% |
| 11 | KRON KRONOS BIO INC | $2.1M | 0.88% |
| 12 | CCCC C4 THERAPEUTICS INC | $1.2M | 0.49% |
Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.